BSECompany Update16h ago · 18 Nov 2026, 03:37 pm

Please find attached.

India Glycols Ltd · 500201

✦ AI Summary▲ PositiveResults

India Glycols Ltd has released an investor presentation for Q2 & H1 FY27, highlighting strong growth momentum, healthy earnings growth, and a shift towards a specialty-led portfolio. The company's bio-based specialty materials and sustainable & performance chemicals segments are demonstrating operating leverage and expanding margins. The demerger of Spirits & Bio-fuels and Ennature Biopharma businesses has created a focused chemicals company.

Analysis Scores

Earnings Impact8/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk4/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

India Glycols Ltd - 500201 - Announcement under Regulation 30 (LODR)-Investor Presentation

Attachments (1)

📄

b2e33d12-c614-46a5-9725-e5c4f1b34d22.pdf

pdf

Download →
View document text
IGL/SE/2026-27/79 18th November, 2026 The Manager (Listing) The Manager (Listing) BSE Limited National Stock Exchange of India Limited 1st Floor, New Trading Ring, Exchange Plaza, C-1, Block G, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Dalal Street, Bandra (East), Mumbai – 400 001 Mumbai- 400 051 Scrip Code: 500201 Symbol: INDIAGLYCO Dear Sirs, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Investor Presentation for Q2 & H1FY27 Earnings Conference Call. Further to our letter bearing no. IGL/SE/2026-27/75 dated 6th November, 2026 and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, an investor presentation is attached for the information of the investors. This same is also being hosted on the Company’s website at www.indiaglycols.com. This is for your information and record. Thanking you, Yours truly, For India Glycols Limited Ankur Jain Head (Legal) & Company Secretary Encl: A/a India Glycols Limited Investor Presentation Q2 & H1 FY27 BSE : 500201 | NSE : INDIAGLYCO SAFE HARBOR This presentation and the following discussion may contain “forward looking statements” by India Glycols Limited (“IGL” or the company) that are not historical in nature. These forward- looking statements, which may include statements relating to future results of operations, financial condition, business prospects, plans and objectives, are based on the current beliefs, assumptions, expectations, estimates, and projections of the management of IGL about the business, industry and markets in which IGL operates. These statements are not guarantees of future performance, and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond IGL’s control and difficult to predict, that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Such statements are not, and should not be construed, as a representation as to future performance or achievements of IGL. In particular, such statements should not be regarded as a projection of future performance of IGL. It should be noted that the actual performance or achievements of IGL may vary significantly from such statements. CONTENTS Q2 & H1 FY27 Performance Highlights Company Overview Historical Financial Highlights IGL Group Before the Demerger Q2 & H1 FY27 Performance Highlights Q2 & H1 FY27 Performance Snapshot Strong Broad-Based Growth and an Improving Business Mix towards a Specialty-Led Portfolio, Support the Long-term Value-Creation Roadmap • Strong Growth Momentum: Q2 FY27 revenue grew 30% YoY to ₹358 Cr, while H1 revenue increased 26% to ₹713 Cr • Healthy Earnings Growth: EBITDA grew 26% YoY to ₹52 Cr in Q2 and 25% to ₹113 Cr in H1 FY27; H1 margin remained stable at 15.8% • Bio-based Specialty Materials Leading Growth: H1 revenue increased 43% YoY to ₹382 Cr, EBITDA up 15% to ₹62 Cr • Sustainable & Performance Chemicals Demonstrating Operating Leverage: Q2 revenue grew 36% to ₹167 Cr and H1 revenue grew 29% to ₹313 Cr, while EBITDA increased 49% to ₹24 Cr in Q2 and 40% to ₹51 Cr in H1; Margin expanded from 13.0% to 14.2% in Q2 and from 15.0% to 16.3% in H1 • Improving Business Mix: Bio-Based Specialty Materials increased its share of H1 revenue to 55% from 52%, supporting the shift toward a more specialty-led portfolio • Outlook: The speciality materials expected to see steady growth going forward, Performance Chemicals would be the growth driver followed by introduction novel products and technologies in the mid to longer time frame. The new product pipe line, business development with diverse partners as well work on newer technology projects. *EBITDA including JV Share Note: Q2 FY26 and H1 FY26 figures have been presented on a like-for-like basis and therefore differ from the consolidated results reported to the stock exchanges, which included Spirits & Bio-fuels and Ennature Biopharma businesses subsequently demerged from India Glycols Limited The Demerger Creates a Focused Chemicals Company FROM ONE GROUP TO THREE LISTED COMPANIES FY26 Consolidated Financials India Glycols Limited (Pre-demerger) FY26 Revenue ₹4,211 Cr · FY26 EBITDA ₹690 Cr IGL Spirits Limited India Glycols Limited Ennature Biopharma Limited Spirits & Bio-fuels Chemicals Nutraceuticals & plant-based APIs Revenue ₹2,801 Cr Revenue ₹1,164 Cr Revenue ₹246 Cr EBITDA ₹492 Cr EBITDA ₹169 Cr EBITDA ₹29 Cr EBITDA margin 17.6% EBITDA margin 14.5% EBITDA margin 11.9% 71% 25% 4% of group EBITDA of group EBITDA of group EBITDA 1 share for every 1 IGL share Continues as the Chemicals business 1 share for every 3 IGL shares WHAT IT MEANS FOR IGL Visible and valued on its own Own capital allocation Continuity at arm's length Chemicals was a quarter of group Cash flows go into capacity fill and Ethanol supply and shared Kashipur EBITDA; it now has its own P&L, specialties, not into spirits or services run on commercial investor base and valuation pharma capex agreements IGL at a Glance : A Pioneer in Plant-based Chemicals in India Since 1989, IGL has converted sugarcane-derived ethanol into ethylene oxide and its derivatives — building blocks for packaging, textiles, coatings, personal care and pharma THREE BUSINESS PLATFORMS 4 Decades 300 Acre Sustainable & of expertise in Green State-of-the-art Bio-based Gases Chemistry Manufacturing facility in Performance Specialty Materials Kashipur Chemicals Bio Glycols, Glycol Ether & GE Bio-amines, green solvents, Industrial, food-grade and Esters application-led chemistries medical gases ₹1,164 Cr ₹169 Cr Scaled renewable molecules Specialty-led growth engine; High-purity, reliability-led with a lower-carbon feedstock includes JV with Clariant supply for essential FY26 revenue EBITDA advantage applications WHAT SETS IGL APART 14.5% 40+ EBITDA margin, +570 bps Countries Global pioneer in bio-EO Integrated, hard-to-replicate chain 01 02 over FY24–26 The world’s 1st producer of Bio-based Ethanol → bio-ethylene → bio-EO → Ethylene Oxide / Bio-based Glycols / Bio- derivatives at one Kashipur complex, rail- based Amines and still one of the few linked to ports. manufacturers to do it at scale ~45% 100+ Structural sustainability tailwind Built-in growth and margin levers 03 04 Export share of sales Customers Drop-in renewable molecules help Capacity headroom, rising specialty mix (ex-JV) customers decarbonize without and R&D-led innovation with global reformulating. partners. Following the demerger of its spirits and biopharma businesses, IGL is a pure-play chemicals company Key Strengths of the Renewable Chemistry Platform Integrated Bio-EO Deep Process Global, Diversified Pure-play Focus Platform Know-how Reach Dedicated management and One platform, multiple ways to ~4 decades of expertise, end- 12+ end-markets served across capital allocation; valued on its monetise every molecule to-end integration and trusted 40+ countries own economics partnerships Feedstock to Chemistry-led Favourable Experienced Finished Product Breadth Industry Dynamics Leadership Flexible sourcing and rail-linked 1 renewable feedstock, 19 Demand shift to bio-based Seasoned board and a access to global markets derivatisation platforms, 28 chemicals dedicated leadership team for application functions IGL One Integrated Platform, Multiple Ways to Monetise Every Molecule A vertically integrated chain from renewable ethanol to five revenue streams — pioneered by IGL in 1989 and refined over 4 Decades INTEGRATED VALUE CHAIN INTEGRATED VALUE CHAIN 97% 1989 Bio-Glycols (MEG · DEG · TEG) Packaging, Polyester Fibre, Coolants Renewable raw material First to produce EO from renewable ethanol Glycol Ethers & GE Esters Paints, coatings, inks, automotive Performance Chemicals Application-led specialty ingredients Renewable Ethanol Sugarcane-based, incl. CarbonSmart Bio-Ethylene Bio-EO Bio-EO [Showing first 8,000 characters — download PDF for full document]